A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene - STELLAR

ProQR Therapeutics0 sites18 target enrollmentNovember 16, 2018

Overview

No summary available.

Registry

who.int

Start Date

November 16, 2018

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

•Male or female, \= 18 years of age.
•Clinical presentation consistent with RP with Usher syndrome type 2 or NSRP, based on ophthalmic, audiologic, and vestibular examinations.
•An ERG result consistent with RP with Usher syndrome type 2 or NSRP.
•A molecular diagnosis of homozygosity or compound heterozygosity for 1 or more pathogenic exon 13 mutations in the USH2A gene, based on genetic analysis upon Sponsor approval.
•No limitations to OCT image collection that would prevent high quality, reliable images from being obtained in both eyes (including outer segment \[OS] thickness and volume, outer nuclear layer \[ONL] thickness, total receptor (TR) thickness, EZ horizontal and vertical widths, apparent continuous EZ area, central macula thickness \[CMT], grading of cystic macular lesions \[CML] if any), as determined by the reading center.
•Reliable perimetry measurements in both eyes, as described in the Study Reference Manual and determined by the reading center.
•Clear ocular media and adequate pupillary dilation to permit good quality retinal imaging, as assessed by the Investigator.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes

•Presence of additional non\-exon 13 USH2A pathogenic mutation(s) on the USH2A allele carrying the exon 13 mutation in subjects who are compound heterozygous for mutations in exon 13\.
•Presence of non\-exon 13 USH2A pathogenic mutation(s) on both USH2A alleles in subjects who are homozygous for mutations in exon 13\.
•Presence of pathogenic mutations in genes (other than the USH2A gene) associated with Usher syndrome Type 2 or NSRP, or other inherited retinal degenerative diseases or syndromes.
•Any contraindication to IVT injection according to the Investigator’s clinical judgment and international guidelines.
•Nystagmus or unstable fixation.
•Amblyopia.
•Prior receipt of intraocular surgery or procedure or IVT injection within 12 weeks prior to study start or planned intraocular surgery or procedure during the course of the study.
•Any prior treatment with genetic therapy.